Merus to Present at the Canaccord Genuity 45th Annual Growth Conference

Rhea-AI Summary

Merus (NASDAQ: MRUS), a company specializing in oncology and developing innovative multispecific antibodies and antibody drug conjugates, has announced its participation in the Canaccord Genuity 45th Annual Growth Conference. Bill Lundberg, M.D., the company's President and CEO, will engage in a fireside chat on Wednesday, August 13, 2025, at 1:30 p.m. ET.

The presentation will be available via webcast on the Investors section of Merus's website, with an archived version accessible for a limited time following the event.

News Market Reaction – MRUS

-2.83%

4 alerts

-2.83% Session close to close

$4.71B Market Cap

0.0x Rel. Volume

In the Aug 6 session, MRUS declined 2.83%, reflecting a moderate negative market reaction. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UTRECHT, The Netherlands and CAMBRIDGE, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics^®, Triclonics^® and ADClonics^®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the Canaccord Genuity 45^th Annual Growth Conference on Wednesday, August 13, 2025 at 1:30 p.m. ET.

The webcast of the presentation will be contemporaneously available on the Investors page of the Company's website. The archived presentation will also be available there for a limited time after the event.

About Merus
Merus is an oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics^®. Multiclonics^® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website, LinkedIn and Bluesky.

Multiclonics^®, Biclonics^®, Triclonics^® and ADClonics^® are registered trademarks of Merus N.V.

Investor and Media Inquiries:
Sherri Spear
Merus N.V.
SVP Investor Relations and Strategic Communications
617-821-3246
s.spear@merus.nl

Kathleen Farren
Merus N.V.
Director IR/Corp Comms
617-230-4165
k.farren@merus.nl

FAQ

When is Merus (MRUS) presenting at the Canaccord Genuity Growth Conference 2025?

Merus will present on Wednesday, August 13, 2025 at 1:30 p.m. ET through a fireside chat with CEO Bill Lundberg, M.D.

Who will represent Merus (MRUS) at the Canaccord Genuity Conference?

Bill Lundberg, M.D., who serves as President and Chief Executive Officer of Merus, will represent the company.

How can investors access Merus's (MRUS) presentation at the Canaccord Conference?

The presentation will be available via live webcast on the Investors page of Merus's website, with an archived version available for a limited time after the event.

What type of company is Merus (MRUS)?

Merus is an oncology company that develops innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®).